Hemab Therapeutics Holdings, Inc. (COAG) Reports Sutacimig PT Shortened Over 50% After One Dose

Hemab Therapeutics (COAG) reported that sutacimig reduced prothrombin time by over 50% in two patients with severe Factor VII deficiency after one dose. One patient showed a 5x increase in endogenous FVII(a) by Day 22. HMB-003 reduced severe bleeding days in a monkey model. Further data is expected in mid-2027.

Original reporting
Published Nov 4, 2026, 2:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hemab Therapeutics Holdings, Inc. (COAG) Reports Sutacimig PT Shortened Over 50% After One Dose — source image
Decision brief

The 30-second read

$COAGBullishLow
01

Why it matters

The >50% shortening of prothrombin time suggests the drug engages its target, potentially accelerating the path to later‑stage trials and partnership interest.

02

Market read

First‑report clinical data for a micro‑cap biotech; could spark short‑term price movement and attract speculative interest.

03

What to watch

Regulatory timeline and funding needs for Phase 1/2 trials could constrain upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Hemab Therapeutics (COAG) is a clinical‑stage biotech focused on rare coagulation disorders. The company recently announced its first human dose data for sutacimig.

Company-level read

Ticker impact

$COAGBullishMedium confidence
Context

Hemab Therapeutics reported that two severe Factor VII deficiency patients showed >50% prothrombin time shortening after a single sutacimig dose, indicating early clinical efficacy.

Expected impact

potential upside as the market prices in the encouraging efficacy signal

Evidence & confidence

Early human data and preclinical results are novel and material for a micro‑cap biotech, but further trials are needed before a decisive move.

Market effects

May boost interest in rare‑disease gene‑therapy and coagulation‑disorder pipelines.

Limited to US biotech investors; no broad regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

Early data could be over‑hyped; small sample size and lack of control may limit price reaction.

Key entities

  • Hemab Therapeutics Holdings, Inc.

    US‑listed biotech developing sutacimig for Factor VII deficiency.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A